Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Revenue projections:

Revenue projections for ABT
Revenue projections for ABT

The projected decline in ABT's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.376000
forwardPE 18.346973
debtToEquity 63.212000
earningsGrowth -0.475000
revenueGrowth 0.130000
grossMargins 0.568470
operatingMargins 0.147070
trailingEps 3.090000
forwardEps 6.063670

ABT's current ratio of 1.376 shows that the company has ample resources to service its short-term debt. This indicates a solid financial position, as ABT can rely on its cash reserves and current assets to cover its immediate liabilities without strain.
ABT's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
ABT's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
ABT's negative gross and operating margins reflect unprofitability, suggesting the company is unable to generate revenue sufficient to cover its costs. This could indicate deeper financial challenges or declining efficiency.
ABT's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that ABT's financial performance will improve in the current financial year.

Price projections:

Price projections for ABT
Price projections for ABT

ABT's stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.

Insider Transactions:

Insider Transactions for ABT
Insider Transactions for ABT


3 ABT sales were executed, with market price at 125.48333485921223.5 separate transactions to buy ABT were completed, while market price hovered around 97.58200073242188.The transactions conducted by insiders do not indicate any significant pattern, leaving little to infer about the company’s strategic moves.

Recommendation changes over time:

Recommendations trend for ABT
Recommendations trend for ABT


A recent buy bias from analysts toward Abbott Laboratories indicates strong confidence in the stock's future performance. This could encourage investors to park their money in Abbott Laboratories, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.